GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results

Why did Regeneron buy 23andMe for $256M? How will US credit downgrade impact markets? Why is Walmart raising prices due to tariffs? What led JPMorgan to warn about stagflation? How did China respond to US Huawei chip restrictions? Why is Nvidia partnering to scale AI infrastructure? What does the UK-EU post-Brexit reset entail? How will Trump’s tax bill affect the economy? Why is Blink Charging cutting workforce by 20%?

GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results

benzinga.com/general/biotech/25/05/45491690/exclusive-gt-biopharma-advances-relapsed-blood-cancer-therapy-trial-to-cohort-2-after-promising-e

GT Biopharma, Inc. (NASDAQ:GTBP) announced Monday that it has successfully completed dosing in Cohort 1 and started dosing in Cohort 2 of its Phase 1 dose escalation trial for GTB-3650. The therapy is a second-generation TriKE therapeutic targeting relapsed or refractory CD33-expressing…

This story appeared on benzinga.com, 2025-05-19 12:30:12.